Quality of life compared during pharmacological treatments and clinical monitoring for non‐localized prostate cancer: a randomized controlled trial

To investigate the effects of different management strategies for non‐localized prostate cancer on men's quality of life and cognitive functioning.

[1]  N. Vogelzang,et al.  Quality of life and psychosocial status in stage D prostate cancer , 1992, Quality of Life Research.

[2]  R. Gardiner,et al.  Coping and health‐related quality of life in men with prostate cancer randomly assigned to hormonal medication or close monitoring , 2002, Psycho-oncology.

[3]  R. Gardiner,et al.  Altered cognitive function in men treated for prostate cancer with luteinizing hormone‐releasing hormone analogues and cyproterone acetate: a randomized controlled trial , 2002, BJU international.

[4]  T. Wilt,et al.  Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. , 2001, The Cochrane database of systematic reviews.

[5]  A. Mariani,et al.  Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study. , 2001, The Journal of urology.

[6]  T. Tammela,et al.  Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. , 2000, The Journal of urology.

[7]  L. Klotz.  Hormone therapy for patients with prostate carcinoma , 2000, Cancer.

[8]  H. Herr,et al.  Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. , 2000, The Journal of urology.

[9]  L. Collette,et al.  Prostate cancer treated by anti-androgens: is sexual function preserved? , 2000, British Journal of Cancer.

[10]  R. Stege.  Potential side‐effects of endocrine treatment of long duration in prostate cancer , 2000, The Prostate. Supplement.

[11]  Bhayani Sb,et al.  Hormonal manipulation for rising PSA after radical prostatectomy. , 1999 .

[12]  S. Arver,et al.  Factors associated with waning sexual function among elderly men and prostate cancer patients. , 1997, The Journal of urology.

[13]  B. Sherwin,et al.  "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. , 1997, The Journal of clinical endocrinology and metabolism.

[14]  S. Arver,et al.  Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: a population-based study. , 1996, Age and ageing.

[15]  I. Tummon,et al.  Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study. , 1996, Fertility and sterility.

[16]  S. Fosså,et al.  The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853. , 1996, European journal of cancer.

[17]  A. Friedman,et al.  Adverse effects of leuprolide acetate depot treatment. , 1993, Fertility and sterility.

[18]  C. Kortepeter,et al.  Possible Short-Term Memory Loss Associated with Nafarelin Acetate , 1992, The Annals of pharmacotherapy.